User profiles for "author:Benjamin Terrier"
 | Benjamin TerrierCochin Hospital, Professor of Internal Medicine Verified email at aphp.fr Cited by 26049 |
IgA vasculitis (Henoch–Shönlein purpura) in adults: Diagnostic and therapeutic aspects
A Audemard-Verger, E Pillebout, L Guillevin… - Autoimmunity …, 2015 - Elsevier
Immunoglobulin A (IgA) vasculitis, formerly called Henoch–Schönlein purpura, is an immune
complex vasculitis affecting small vessels with dominant IgA deposits. Clinical …
complex vasculitis affecting small vessels with dominant IgA deposits. Clinical …
Alpha-enolase: a target of antibodies in infectious and autoimmune diseases
B Terrier, N Degand, P Guilpain, A Servettaz… - Autoimmunity …, 2007 - Elsevier
Alpha-enolase, also called non-neuronal enolase, belongs to a family of cytoplasmic and
glycolytic enzymes. In addition to its glycolytic function, alpha-enolase exerts many other …
glycolytic enzymes. In addition to its glycolytic function, alpha-enolase exerts many other …
[HTML][HTML] Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare anti-neutrophil cytoplasmic
antibody (ANCA)-associated vasculitis, characterized by asthma, eosinophilia and …
antibody (ANCA)-associated vasculitis, characterized by asthma, eosinophilia and …
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
Coronavirus disease 2019 (COVID-19) is characterized by distinct patterns of disease
progression that suggest diverse host immune responses. We performed an integrated …
progression that suggest diverse host immune responses. We performed an integrated …
Autoantibodies against type I IFNs in patients with life-threatening COVID-19
P Bastard, LB Rosen, Q Zhang, E Michailidis… - Science, 2020 - science.org
INTRODUCTION Interindividual clinical variability is vast in humans infected with severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), ranging from silent infection to …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), ranging from silent infection to …
[HTML][HTML] Serum neutralization of SARS-CoV-2 Omicron sublineages BA. 1 and BA. 2 in patients receiving monoclonal antibodies
The severe acute respiratory syndrome coronavirus 2 Omicron BA. 1 sublineage has been
supplanted in many countries by the BA. 2 sublineage. BA. 2 differs from BA. 1 by about 21 …
supplanted in many countries by the BA. 2 sublineage. BA. 2 differs from BA. 1 by about 21 …
Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data
M Mahévas, VT Tran, M Roumier, A Chabrol, R Paule… - Bmj, 2020 - bmj.com
Objective To assess the effectiveness of hydroxychloroquine in patients admitted to hospital
with coronavirus disease 2019 (covid-19) pneumonia who require oxygen. Design …
with coronavirus disease 2019 (covid-19) pneumonia who require oxygen. Design …
[HTML][HTML] Angiopoietin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of COVID-19 patients
Abstract Background Coronavirus disease-2019 (COVID-19), a respiratory disease has
been associated with ischemic complications, coagulation disorders, and an endotheliitis …
been associated with ischemic complications, coagulation disorders, and an endotheliitis …
Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French autoimmunity and rituximab registry
Objective A number of open‐label studies have suggested the potential benefit of rituximab
(RTX) in systemic lupus erythematosus (SLE). However, in 2 recent randomized controlled …
(RTX) in systemic lupus erythematosus (SLE). However, in 2 recent randomized controlled …
No evidence of clinical efficacy of hydroxychloroquine in patients hospitalised for COVID-19 infection and requiring oxygen: results of a study using routinely collected …
M Mahévas, VT Tran, M Roumier, A Chabrol, R Paule… - medrxiv, 2020 - medrxiv.org
Background Treatments are urgently needed to prevent respiratory failure and deaths from
coronavirus disease 2019 (COVID-19). Hydroxychloroquine (HCQ) has received worldwide …
coronavirus disease 2019 (COVID-19). Hydroxychloroquine (HCQ) has received worldwide …